333 related articles for article (PubMed ID: 18707633)
21. Combined use of chemotherapy and 131I-metaiodobenzylguanidine in the treatment of advanced-stage neuroblastoma.
Sari O; Uğur O; Emir S; Akyüz C
Turk J Pediatr; 2001; 43(1):29-33. PubMed ID: 11297155
[TBL] [Abstract][Full Text] [Related]
22. Promising therapeutic targets in neuroblastoma.
Matthay KK; George RE; Yu AL
Clin Cancer Res; 2012 May; 18(10):2740-53. PubMed ID: 22589483
[TBL] [Abstract][Full Text] [Related]
23. Iodine-131-metaiodobenzylguanidine as initial induction therapy in stage 4 neuroblastoma patients over 1 year of age.
de Kraker J; Hoefnagel KA; Verschuur AC; van Eck B; van Santen HM; Caron HN
Eur J Cancer; 2008 Mar; 44(4):551-6. PubMed ID: 18267358
[TBL] [Abstract][Full Text] [Related]
24. Nothing but NET: a review of norepinephrine transporter expression and efficacy of 131I-mIBG therapy.
Streby KA; Shah N; Ranalli MA; Kunkler A; Cripe TP
Pediatr Blood Cancer; 2015 Jan; 62(1):5-11. PubMed ID: 25175627
[TBL] [Abstract][Full Text] [Related]
25. Iodine-131 metaiodobenzylguanidine therapy for neuroblastoma: reports so far and future perspective.
Kayano D; Kinuya S
ScientificWorldJournal; 2015; 2015():189135. PubMed ID: 25874239
[TBL] [Abstract][Full Text] [Related]
26. Correlation of tumor and whole-body dosimetry with tumor response and toxicity in refractory neuroblastoma treated with (131)I-MIBG.
Matthay KK; Panina C; Huberty J; Price D; Glidden DV; Tang HR; Hawkins RA; Veatch J; Hasegawa B
J Nucl Med; 2001 Nov; 42(11):1713-21. PubMed ID: 11696644
[TBL] [Abstract][Full Text] [Related]
27. 131I-metaiodobenzylguanidine therapy of neuroblastoma and other neuroendocrine tumors.
Grünwald F; Ezziddin S
Semin Nucl Med; 2010 Mar; 40(2):153-63. PubMed ID: 20113683
[TBL] [Abstract][Full Text] [Related]
28. [Thyroid dysfunction due to 131I-metaiodobenzylguanidine in patients with neuroblastoma].
Garrido Magaña E; Silva Estrada JA; Nishimura Meguro E; Rivera Hernández AJ; Zurita Cruz JN
Rev Chil Pediatr; 2020 Jun; 91(3):379-384. PubMed ID: 32730518
[TBL] [Abstract][Full Text] [Related]
29. Safety and efficacy of tandem 131I-metaiodobenzylguanidine infusions in relapsed/refractory neuroblastoma.
Johnson K; McGlynn B; Saggio J; Baniewicz D; Zhuang H; Maris JM; Mosse YP
Pediatr Blood Cancer; 2011 Dec; 57(7):1124-9. PubMed ID: 21495159
[TBL] [Abstract][Full Text] [Related]
30. Engraftment after myeloablative doses of 131I-metaiodobenzylguanidine followed by autologous bone marrow transplantation for treatment of refractory neuroblastoma.
Goldberg SS; DeSantes K; Huberty JP; Price D; Hasegawa BH; Reynolds CP; Seeger RC; Hattner R; Matthay KK
Med Pediatr Oncol; 1998 Jun; 30(6):339-46. PubMed ID: 9589082
[TBL] [Abstract][Full Text] [Related]
31. The role of 131I-MIBG in high-risk neuroblastoma treatment.
Lessig MK
J Pediatr Oncol Nurs; 2009; 26(4):208-16. PubMed ID: 19726792
[TBL] [Abstract][Full Text] [Related]
32. Incidence and risk factors for secondary malignancy in patients with neuroblastoma after treatment with (131)I-metaiodobenzylguanidine.
Huibregtse KE; Vo KT; DuBois SG; Fetzko S; Neuhaus J; Batra V; Maris JM; Weiss B; Marachelian A; Yanik GA; Matthay KK
Eur J Cancer; 2016 Oct; 66():144-52. PubMed ID: 27573428
[TBL] [Abstract][Full Text] [Related]
33. Treatment of advanced neuroblastoma: feasibility and therapeutic potential of a novel approach combining 131-I-MIBG and multiple drug chemotherapy.
Mastrangelo S; Tornesello A; Diociaiuti L; Pession A; Prete A; Rufini V; Troncone L; Mastrangelo R
Br J Cancer; 2001 Feb; 84(4):460-4. PubMed ID: 11207038
[TBL] [Abstract][Full Text] [Related]
34. Comparison of high-specific-activity ultratrace 123/131I-MIBG and carrier-added 123/131I-MIBG on efficacy, pharmacokinetics, and tissue distribution.
Barrett JA; Joyal JL; Hillier SM; Maresca KP; Femia FJ; Kronauge JF; Boyd M; Mairs RJ; Babich JW
Cancer Biother Radiopharm; 2010 Jun; 25(3):299-308. PubMed ID: 20578835
[TBL] [Abstract][Full Text] [Related]
35. [131I]MIBG and topotecan: a rationale for combination therapy for neuroblastoma.
McCluskey AG; Boyd M; Gaze MN; Mairs RJ
Cancer Lett; 2005 Oct; 228(1-2):221-7. PubMed ID: 15935554
[TBL] [Abstract][Full Text] [Related]
36. MIBG in Neuroblastoma Diagnostic Imaging and Therapy.
Sharp SE; Trout AT; Weiss BD; Gelfand MJ
Radiographics; 2016; 36(1):258-78. PubMed ID: 26761540
[TBL] [Abstract][Full Text] [Related]
37. Gene manipulation to enhance MIBG-targeted radionuclide therapy.
Mairs RJ; Fullerton NE; Cosimo E; Boyd M
Nucl Med Biol; 2005 Oct; 32(7):749-53. PubMed ID: 16243651
[TBL] [Abstract][Full Text] [Related]
38. The role of 131I-metaiodobenzylguanidine (MIBG) therapy in unresectable and compromising localised neuroblastoma.
Schoot RA; Bleeker G; Caron HN; van Eck BL; Heij HA; de Kraker J; Tytgat GA
Eur J Nucl Med Mol Imaging; 2013 Oct; 40(10):1516-22. PubMed ID: 23740371
[TBL] [Abstract][Full Text] [Related]
39. Severe oral mucositis after therapeutic administration of [131I]MIBG in a child with neuroblastoma.
Dahllöf G; Borgström P; Lundell G; Jacobsson H; Kogner P
Oral Surg Oral Med Oral Pathol Oral Radiol Endod; 2001 Oct; 92(4):420-3. PubMed ID: 11598577
[TBL] [Abstract][Full Text] [Related]
40. Phase I/II clinical trial of high-dose [
Kuroda R; Wakabayashi H; Araki R; Inaki A; Nishimura R; Ikawa Y; Yoshimura K; Murayama T; Imai Y; Funasaka T; Wada T; Kinuya S
Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1574-1583. PubMed ID: 34837510
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
